Evolving Role of FLT3 Analysis in AML Diagnosis and Management: Presentation and Discussion
When: Monday, May 29, 2023, 7:00 PM EST
Where: Zoom – link will be provided upon registration
Faculty :
Julie Bergeron, MD
Hôpital Maisonneuve-Rosemont, Montreal, QC
José-Mario Capo-Chichi, PhD
University Health Network, Toronto, ON
Hubert Tsui, MD
Sunnybrook Health Sciences Centre, Toronto, ON
Questions to be addressed include:
- What is the clinical relevance in AML of FLT3-ITD and FLT3-TKD mutations?
- Which patients should be tested for FLT3 mutations, and when?
- Which is the preferred method for FLT3 mutation testing?
- What is the clinical relevance of FLT3-ITD size, insertion site and number of distinct mutations?
- Is there a role for FLT3-ITD analysis in MRD assessment?
- What is the clinical relevance of the FLT3-ITD allelic burden? Should it be assessed and if so, how?
- How should results of FLT3 mutation testing be reported?
